Table 2.
Proportion of PPMI de novo PD cohort that met progression milestone criteria at the time of first event or last follow-up
| Data Source | ||
| Variable | Annual Visits* | All Visits** |
| (N = 376) | (N = 385) | |
| Any domain | ||
| Overall (any milestone) | 166 (44.1%) | 193 (50.1%) |
| Cognitive domain | ||
| Overall (any milestone) | 53 (14.1%) | 55 (14.3%) |
| By milestone | ||
| Cognitive impairment (MoCA) | 25 (6.6%) | 19 (4.9%) |
| Dementia (composite) | 13 (3.5%) | 11 (2.9%) |
| Apathy | 11 (2.9%) | 18 (4.7%) |
| Cognitive impairment (MDS-UPDRS) | 10 (2.7%) | 11 (2.9%) |
| Dementia (clinical diagnosis) | 3 (0.8%) | 2 (0.5%) |
| Hallucinations | 1 (0.3%) | 1 (0.3%) |
| Functional dependence domain | ||
| Overall (Schwab &England <80) | 45 (12.0%) | 56 (14.5%) |
| Autonomic dysfunction domain | ||
| Overall (any milestone) | 41 (10.9%) | 39 (10.1%) |
| By milestone | ||
| Incontinence | 20 (5.3%) | 21 (5.5%) |
| Syncope (SCOPA-AUT) | 20 (5.3%) | 17 (4.4%) |
| Syncope (MDS-UPDRS) | 2 (0.5%) | 2 (0.5%) |
| Orthostatic hypotension | 1 (0.3%) | 1 (0.3%) |
| Walking and balance domain | ||
| Overall (any milestone) | 25 (6.6%) | 31 (8.1%) |
| By milestone | ||
| Postural instability | 13 (3.5%) | 22 (5.7%) |
| Walking and balance | 8 (2.1%) | 6 (1.6%) |
| Gait | 7 (1.9%) | 5 (1.3%) |
| Hoehn &Yahr | 3 (0.8%) | 1 (0.3%) |
| Freezing | 2 (0.5%) | 2 (0.5%) |
| Freezing of gait | 1 (0.3%) | 1 (0.3%) |
| Motor complications domain | ||
| Overall (any milestone) | 19 (5.1%) | 23 (6.0%) |
| By milestone | ||
| Fluctuations (complexity) | 10 (2.7%) | 11 (2.9%) |
| Fluctuations (functional impact) | 11 (2.9%) | 14 (3.6%) |
| Dyskinesias | 0 | 0 |
| Activities of daily living domain | ||
| Overall (any milestone) | 17 (4.5%) | 19 (4.9%) |
| By milestone | ||
| Choking | 11 (2.9%) | 12 (3.1%) |
| Speech | 5 (1.3%) | 3 (0.8%) |
| Dressing | 1 (0.3%) | 2 (0.5%) |
| Eating | 1 (0.3%) | 3 (0.8%) |
| Hygiene | 0 | 0 |
For participants who ever reached any milestone, data only considers the initial event (i.e., first visit at which criteria for at least one milestone were met). Columns include participants who were milestone-free at baseline and subsequently completed at least one of the specified follow-up visits. *Derived from follow-up data collected at 12, 24, 36, 48, and 60 months. **Derived from follow-up data collected at 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months. MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic.